trial

Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia

NCTId NCT02354001
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 80 (estimated)
Sponsored by The Alfred
Primary completion 2019-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
80 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2011-04
Primary completion
2019-01
Eligibility
FEMALE · 18 Years · 45 Years

Interventions & indications

Drugs
Raloxifene Hydrochloride

Sponsors

The AlfredLead Sponsor
Monash UniversityCollaborator

Sites

1 total
Melbourne, Australia

Facts & assertions

4 sourced
Enrollment
80
Phase
PHASE4
Primary Completion Date
2019-01
Status
COMPLETED
relationships
The graph out of here
drug
Raloxifene Hydrochloride
drug
lead_sponsor
The Alfred
company
collaborator
Monash University
company
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
Schizophrenia
indication